This specific point mutation has been previously shown to be a gain-of-function alteration that activates IL-2-mediated signaling, promoting malignant T-cell proliferation and survival, thus representing a key oncogenic driver in a subset of MF patients [5]. This evidence concerns the gene IL2 and mycosis fungoides.